Literature DB >> 20417224

Cobra venom factor: Structure, function, and humanization for therapeutic complement depletion.

Carl-Wilhelm Vogel1, David C Fritzinger.   

Abstract

Cobra venom factor (CVF) is the complement-activating protein in cobra venom. This manuscript reviews the structure and function of CVF, how it interacts with the complement system, the structural and functional homology to complement component C3, and the use of CVF as an experimental tool to decomplement laboratory animals to study the functions of complement in host defense and immune response as well as in the pathogenesis of diseases. This manuscript also reviews the recent progress in using the homology between CVF and C3 to study C3 structure and function, and to develop human C3 derivatives with the complement-depleting function of CVF. These human C3 derivatives represent humanized CVF, and are a conceptually different concept for pharmacological intervention of the complement system, therapeutic complement depletion. The use of humanized CVF for therapeutic complement depletion in several pre-clinical models of human diseases is also reviewed.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20417224     DOI: 10.1016/j.toxicon.2010.04.007

Source DB:  PubMed          Journal:  Toxicon        ISSN: 0041-0101            Impact factor:   3.033


  50 in total

1.  Substrate recognition by complement convertases revealed in the C5-cobra venom factor complex.

Authors:  Nick S Laursen; Kasper R Andersen; Ingke Braren; Edzard Spillner; Lars Sottrup-Jensen; Gregers R Andersen
Journal:  EMBO J       Date:  2011-01-07       Impact factor: 11.598

Review 2.  Complement component C3 - The "Swiss Army Knife" of innate immunity and host defense.

Authors:  Daniel Ricklin; Edimara S Reis; Dimitrios C Mastellos; Piet Gros; John D Lambris
Journal:  Immunol Rev       Date:  2016-11       Impact factor: 12.988

3.  Yersinia pseudotuberculosis uses Ail and YadA to circumvent neutrophils by directing Yop translocation during lung infection.

Authors:  Michelle K Paczosa; Michael L Fisher; Francisco J Maldonado-Arocho; Joan Mecsas
Journal:  Cell Microbiol       Date:  2013-11-03       Impact factor: 3.715

4.  Survival of Carbapenem-Resistant Klebsiella pneumoniae Sequence Type 258 in Human Blood.

Authors:  Frank R DeLeo; Scott D Kobayashi; Adeline R Porter; Brett Freedman; David W Dorward; Liang Chen; Barry N Kreiswirth
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

5.  Enhanced recognition of plasma proteins in a non-native state by complement C3b. A possible clearance mechanism for damaged proteins in blood.

Authors:  Mahalakshmi Ramadass; Berhane Ghebrehiwet; Richard R Kew
Journal:  Mol Immunol       Date:  2014-11-15       Impact factor: 4.407

6.  Complement Inhibition: A Novel Form of Immunotherapy for Colon Cancer.

Authors:  Stephanie Downs-Canner; Deepa Magge; Roshni Ravindranathan; Mark E O'Malley; Lily Francis; Zuqiang Liu; Z Sheng Guo; Natasa Obermajer; David L Bartlett
Journal:  Ann Surg Oncol       Date:  2015-08-20       Impact factor: 5.344

7.  Therapeutic inhibition of the alternative complement pathway attenuates chronic EAE.

Authors:  Xianzhen Hu; V Michael Holers; Joshua M Thurman; Trent R Schoeb; Theresa N Ramos; Scott R Barnum
Journal:  Mol Immunol       Date:  2013-01-20       Impact factor: 4.407

8.  Unique neuromyelitis optica pathology produced in naïve rats by intracerebral administration of NMO-IgG.

Authors:  Nithi Asavapanumas; Julien Ratelade; A S Verkman
Journal:  Acta Neuropathol       Date:  2013-11-05       Impact factor: 17.088

9.  Depletion of Complement Enhances the Clearance of Brucella abortus in Mice.

Authors:  Gabriela González-Espinoza; Elías Barquero-Calvo; Esteban Lizano-González; Alejandro Alfaro-Alarcón; Berny Arias-Gómez; Esteban Chaves-Olarte; Bruno Lomonte; Edgardo Moreno; Carlos Chacón-Díaz
Journal:  Infect Immun       Date:  2018-09-21       Impact factor: 3.441

Review 10.  Complement in immune and inflammatory disorders: therapeutic interventions.

Authors:  Daniel Ricklin; John D Lambris
Journal:  J Immunol       Date:  2013-04-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.